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Obesity is endemic in many parts of the 
world, with little signs of abating. If obesity 
continues to increase at the current rate, it is 
estimated that well over 1 billion people in 
the world will be overweight or obese by 
2050. This, together with a media driven 
vision of the ‘ideal body’ having little or no 
body-fat, is distorting the true place of 
adipose tissue in human physiology and its 
importance to human health. This negative 
view is best exemplified by a survey of young 
girls whose number one ‘magic wish’ was be 
thin (Kilbourne, 1994). Clearly, a re-
balancing of our attitude to fat is urgently 
required. It is essential that we have a better 
understanding of the different functions of 
adipose tissue and how content and 
distribution can affect our health. It is 
essential to dispel the current dogma that all 
body-fat is bad and undesirable; at the same 
time we need to become more aware of the 
physiological cost of carrying too much 
body-fat and the health implications of 
depositing it in the ‘wrong’ places. 
The anatomy of adipose tissue
 
Adipose tissue (AT) is a beautiful and 
complex organ fundamental for the optimal 
functioning of our bodies, affecting virtually 
all organs and cell types, mainly through the 
production of chemical signals known as 
adipokines. Adipose tissue is associated with 
many fundamental physiological functions, 
including fertility and immune responses, 
affording us protection from the 
environment, as well as modulation of our 
moods and appetite. Adipose tissue can be 
found in almost every part of our anatomy 
making it the largest organ in our body, from 
the large subcutaneous depots covering our 
bodies (especially around the waist and hips), 
to distinct depots behind our eyes, around 
our heart and behind the knees (Fig. 1).
In the general adult population, levels of 
adipose tissue ranges from 3.5 to 98.0 kg, 
corresponding to a percentage body-fat of 
4.0–68.0%. So what is the right amount of 
AT for an adult? At present we do not have 
exact values for this, but, in terms of a 
healthy percentage body-fat, it is 
recommended that women aim for 21–24%, 
while men should aim for 14–17% 
(Jeukendrup & Gleeson, 2010). Similarly, it is 
suggested that the percentage body-fat for 
women should not go below 10–13% or 
2–5% for men, referred to as essential fat 
percentage; extremely low levels of AT are 
known to be associated with metabolic 
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proportion and quantity- fundamental to many physiological functions.  
Too much body fat, however, is strongly associated with diseases such as 
Type II diabetes, cardiovascular diseases and some forms of cancer. Body  
fat is more than just a passive tissue and an improved understanding of its 
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With the discovery of leptin, adipose tissue (commonly referred to as 
‘body-fat’) was transformed from a humble tissue to a complex and 
intricate organ. Today we know that adipose tissue interacts with virtually 
every organ in the body to ensure optimal homeostasis. Yet, most people 
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role in maintaining our health. But the story of adipose tissue is not as 
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contraindications, as well as affecting fertility 
and immune responses to injury and 
infection. Moreover, let us not forget that 
individuals with lipodystrophy (a genetic 
condition where AT levels are extremely low 
or virtually absent) suffer from many of the 
metabolic conditions observed in obesity 
(Capeau et al., 2010).
At a cellular level adipose tissue can be 
broadly defined as being composed of 
adipocytes, endothelial and nerve cells 
(innervation), as well as inflammatory cells 
including macrophages, neutrophils and 
lymphocytes. Adipocytes, which are the 
principal component of adipose tissue, can in 
turn be subdivided into ‘white’ (responsible 
lipid storage and production of most 
adipokines), ‘brown’ (associated with 
thermogenesis – its presence in adults only 
recently being confirmed) and ‘beige’ (a sort 
of half-way house between the first two,  
but with quite distinct properties)  
(Park et al., 2014).
Indeed the concept of ‘beige fat’ has recently 
attracted much attention given its potential 
as an anti-obesity mechanism. It turns out 
that a number of physiological events, 
including exercise, as well as some natural 
and pharmacological compounds can increase 
the thermogenic properties of subcutaneous 
adipose tissue through a process that has 
come to be known as ‘browning’ (Bartelt & 
Heeren, 2014). It is currently unclear if the 
process of browning takes place by increasing 
expression of thermogenic-UCP1 in white 
adipocyte or by the recruitment of dormant 
‘beige adipocytes’. Regardless, the overall 
effect is an increase in whole-body energy 
expenditure and a reduction in weight and 
adipose tissue, along with an improvement in 
glucose homeostasis.
Levels of other cells are highly dependent on 
the ‘health’ status of the individual, with for 
example inflammatory cells increasing 
significantly in number with obesity, making 
up to 50% of cells in some adipose tissue 
depots. These cells are crucial in the chronic 
and low-grade state of inflammation normally 
associated with increased adiposity, 
especially abdominally obesity.
Adipose tissue content and 
distribution: implications for health 
and well-being
It is now generally accepted that increased 
body adiposity can lead to a plethora of 
metabolic complications including the 
metabolic syndrome, insulin resistance, type 
II diabetes, cardiovascular disease and some 
forms of cancer. At population level the 
relative risk of developing these disorders 
appears to increase linearly with increases in 
AT content. Although most of these studies 
were based on the use of body mass index 
(BMI) as a measure of adiposity, the advent 
of non-invasive imaging techniques, 
especially magnetic resonance imaging (MRI), 
have confirmed some of these findings. 
Moreover, the capability to directly 
determine total and regional content has 
shown that adipose tissue distribution is  
also important.
We now know for example that ‘abdominal 
obesity’ (adipose tissue around the abdomen, 
both subcutaneous and intra-abdominal – 
also known as ‘visceral fat’) does not carry 
the same risk as ‘peripheral adiposity’ 
(adipose tissue around hips and thighs). If 
anything, the latter is seen as benign and 
even cardioprotective, especially gluteal–
femoral adipose tissue. On the other hand 
deposition of visceral adipose tissue is 
strongly associated with the metabolic 
syndrome, insulin resistance and type II 
diabetes. So it is not only the quantity but 
also the distribution of adipose tissue that 
determines the relative risk observed with 
increased adiposity.
Ectopic fat
Beside fat accumulation in adipose tissue, 
lipids in the form of triglycerides can also be 
deposited in the liver (intra-hepatocellular 
lipid, IHCL), muscle (intramyocellular lipid 
IMCL), pancreas (intra-pancreatic cellular 
lipid, IPCL) and heart. These fat depots are 
part of what is known as ‘ectopic fat’, some 
of which appear to be independent risk 
factors for the development of type II 
diabetes (Fig. 2) (Thomas & Bell, 2006). 
Indeed, an extensive number of published 
studies have shown that IHCL is an 
independent risk factor for insulin resistance, 
while IPCL appears to play an important role 
in the process of pancreatic dysfunction 
through ‘lipotoxicity’. Elevation of ectopic fat 
in liver and pancreas is closely associated 
with central obesity and although the exact 
mechanism is not fully understood, it may in 
part arise from the inability of adipose tissue 
in some individuals to efficiently sequestrate 
circulating plasma triglycerides and free  
fatty acids.
Today, like obesity, the number of individuals 
presenting elevated IHCL is reaching 
epidemic proportions, with reports from the 
UK and USA putting the number of cases in 
the general population to over 45% 
(Szczepaniak et al., 2005). The concern over 
elevated IHCL goes beyond its direct effect 
on insulin sensitivity, since we know that 
fatty-liver can eventually progress into liver 
fibrosis and liver cancer (hepatocellular 
carcinomas – HCCs) (Powell et al., 1990).
Adipose tissue distribution: MHO, 
MONW and TOFIs
Over a decade ago Prentice and Jebb wrote a 
seminal review entitled ‘Beyond body mass 
index’, in which they summarised some of the 
Figure 1. Coronal MR image from a healthy 
female volunteer, adipose tissue (and bone 
marrow) appears as bright white in this 
image and can be seen both covering the 
outside of the body (subcutaneous adipose 
tissue) as well as within the body (internal 
adipose tissue).
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Figure 2. ME heat map from subjects with low IHCL (2.9%) and high IHCL (26.1%) content. Increasing IHCL content is shown by the colour 
map changing from blue (low) to red (high).
Figure 3. Coronal MRI images from four male subjects, classified from their adipose tissue distribution as (a) lean control BMI 25.5 kg/m2, 
IAAT = 1.0 litres; (b) TOFI BMI 25.8 kg/m2, IAAT = 4.6 litres; (c) obese control BMI 36.9 kg/m2, IAAT = 5.6 litres; (d) MHO BMI 36.4 kg/m2, 
IAAT = 0.9 litres.
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shortcomings of what was seen at the time 
as the main tool for assessing body adiposity, 
principally BMI (Prentice & Jebb, 2001). 
Central to their argument, and those of 
others, was that the BMI of a subject said 
little about the actual body composition of 
that individual, even less about the 
distribution of adipose tissue. Put simply, a 
body-builder and a morbidly obese person 
would be categorised as having the same 
BMI, despite the fact that the levels of 
skeletal muscle and adipose tissue are 
completely different. Indeed, just recently 
the story of a sportswoman who was told by 
an NHS nurse to go on a strict diet purely 
based on her high BMI hit the headlines 
(Metro, 2014). This is an all too common 
happening for many athletes with a high 
degree of musculature.
Similarly, subjects with a similar BMI and 
overall level of adiposity, but a totally 
different adipose tissue distribution are 
usually assumed to have the same risk of 
disease. However, as we now well know, 
differences in adipose tissue distribution 
convey a very different risk of metabolic 
disease. Differences in adipose tissue 
distribution arising from sex are a good 
example of this, where men present more 
abdominal adiposity than women and 
consequently carry a higher risk of metabolic 
disease. Similarly when women go through 
the menopause, despite minor changes in 
body weight, significant changes in adipose 
tissue distribution are observed, reflecting 
increasing risk of metabolic disease.
Since then, and with the introduction of MRI 
and CT in clinical studies, the importance of 
accurately determining adipose tissue 
distribution has become abundantly clear. 
Subjects matched for BMI and waist-to-hip 
ratio can have significantly different levels of 
visceral adipose tissue and ectopic fat 
(Thomas et al., 2012). These differences 
were crucial in unravelling the metabolic and 
physiological differences observed between 
subjects with identical anthropometric 
parameters. In turn this led to the 
identification of a number of subphenotypes, 
including the ‘metabolically healthy obese’ 
(MHO), the ‘metabolically obese but 
normal-weight’ (MONW) and the ‘TOFI’ 
(thin-outside-fat-inside) individuals (Fig. 3). 
Each of these sub-phenotypes represents 
significant variations in adipose tissue 
distribution and relative risk of developing 
insulin resistance or type-2 diabetes. Thus, it 
is no longer possible to define subjects simply 
based on BMI or other anthropometric 
dimensions; accurate assessment of adipose 
tissue distribution has become essential for 
human studies of obesity and associated risk 
factors.
Metabolically healthy obese (MHO or 
‘fat-fit’) subjects have been reported by a 
number of groups and refer to individuals 
with increased BMI (and in some cases 
waist-hip ratio), carrying considerable levels 
of adipose tissue while still maintaining 
normal insulin sensitivity, blood pressure, 
high HDL and low levels of plasma 
triglycerides (Wildman et al., 2008). The best 
example of this subphenotype is of course 
Sumo wrestlers, many of whom have BMI 
well above 40 kg/m2. There are those of 
course that dispute the existence of true 
MHO subjects, as they consider any form of 
obesity as being ‘unhealthy’, pointing out 
that all MHO individuals do present with 
some metabolic abnormalities, especially 
those associated with inflammatory markers.
Another important subphenotype, the 
‘metabolically obese but normal-weight 
(MONW), comprises lean subjects (BMI <25 
kg/m2) with metabolic profiles normally 
observed in the obese, including reduced 
insulin sensitivity, reduced HDL and raised 
blood pressure (Ruderman et al., 1981). With 
the advent of MRI this subphenotype has 
been further refined, known as ‘TOFI’ 
(thin-outside-fat-inside), showing that 
central to its dysfunctional metabolic profile 
is a disproportionate deposition of visceral 
adipose tissue (Fig. 3), in some cases 
accompanied by elevated IHCL (Thomas et 
al., 2012). This subphenotype can be found 
in a significant proportion of the lean 
population (>10%), especially amongst those 
that aim to maintain a ‘normal weight’ 
through diet-based lifestyle choices, with 
little or no physical activity.
Life-style choices for a healthy 
adipose tissue
The importance of adipose tissue to our 
health cannot be over-stated. Adipose tissue 
should not be seen as the passive tissue 
whose sole purpose was to store excess 
energy in the form of fat. Adipose tissue is a 
complex organ with a crucial role in 
maintaining whole body homeostasis. 
Moreover, it is no longer about how much 
adipose tissue we carry, but also its 
distribution. The lifestyle choices we make 
will impact on adipose tissue distribution as 
well as content, so we need to ensure that 
both a healthy diet and a significant amount 
of physical activity are part of everyday life. 
We need to focus more on fitness rather than 
thinness. Be nice to your adipose tissue and 
your adipose tissue will be nice to you.
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